Your browser doesn't support javascript.
loading
Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model.
Escorcia, Freddy E; Steckler, Jeffrey M; Abdel-Atti, Dalya; Price, Eric W; Carlin, Sean D; Scholz, Wolfgang W; Lewis, Jason S; Houghton, Jacob L.
Afiliación
  • Escorcia FE; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • Steckler JM; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • Abdel-Atti D; Weill Cornell Medical College, 1300 York Ave, New York, NY, 10065, USA.
  • Price EW; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • Carlin SD; Weill Cornell Medical College, 1300 York Ave, New York, NY, 10065, USA.
  • Scholz WW; Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
  • Lewis JS; Weill Cornell Medical College, 1300 York Ave, New York, NY, 10065, USA.
  • Houghton JL; Weill Cornell Medical College, 1300 York Ave, New York, NY, 10065, USA.
Mol Imaging Biol ; 20(5): 808-815, 2018 10.
Article en En | MEDLINE | ID: mdl-29508263
PURPOSE: Tumor-specific molecular imaging is an important tool for assessing disease burden and treatment response. CA19.9 is an important tumor-specific marker in several malignancies, including urothelial carcinoma. [89Zr]DFO-HuMab-5B1 (MVT-2163) is a CA19.9-specific antibody-based construct that has been validated in preclinical animal models of lung, colorectal, and pancreatic malignancies for positron emission tomography (PET) imaging and is currently in a phase I trial for pancreatic cancer (NCT02687230). Here, we examine whether [89Zr]DFO-HuMab-5B1 may be useful in defining urothelial malignancies. PROCEDURES: Surface expression of CA19.9 was confirmed in the human bladder cancer line HT 1197. The radioimmunoconjugate [89Zr]DFO-HuMab-5B1 was injected into mice bearing HT 1197 xenografts, and followed by PET imaging, ex vivo experiments including biodistribution, histology and autoradiography, and analysis of blood samples for shed antigen levels were performed. RESULTS: [89Zr]DFO-HuMab-5B1 specifically accumulates in HT 1197 engrafted tumors when imaged with PET. Ex vivo biodistribution of organs and autoradiography of engrafted tumors confirm our construct's specific tumor binding. The target antigen CA19.9 was not found to be shed in vitro or in vivo. CONCLUSIONS: [89Zr]DFO-HuMab-5B1 can be used to delineate urothelial carcinomas by PET imaging and may provide tumor-specific information prior to, during, and after systemic therapies.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Radioisótopos / Circonio / Neoplasias de la Vejiga Urinaria / Tomografía de Emisión de Positrones / Modelos Biológicos Idioma: En Revista: Mol Imaging Biol Asunto de la revista: BIOLOGIA MOLECULAR / DIAGNOSTICO POR IMAGEM Año: 2018 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Radioisótopos / Circonio / Neoplasias de la Vejiga Urinaria / Tomografía de Emisión de Positrones / Modelos Biológicos Idioma: En Revista: Mol Imaging Biol Asunto de la revista: BIOLOGIA MOLECULAR / DIAGNOSTICO POR IMAGEM Año: 2018 Tipo del documento: Article